Abstract: A display panel is provided. The display panel includes: a pixel definition layer including light-emitting openings in an array distribution; a light-emitting layer disposed in the light-emitting openings; and photosensitive elements disposed above the pixel definition layer, wherein projections of the photosensitive elements on the pixel definition layer are located outside the light-emitting openings. According to the present disclosure, the photosensitive elements are disposed obliquely above the light-emitting openings of the display panel. In this way, the photosensitive elements can more effectively sense the light emitted upward from the light-emitting layer and perform signal feedback.

Abstract: Provided are a fused tricyclic compound having the structure shown in formula (I), a pharmaceutical composition thereof, and a use thereof. The fused tricyclic compound serves as a selective inhibitor of KRAS mutation, and has high activity, good selectivity. and reduced toxic side effects.

Abstract: Provided are a dihydronaphthyridinone compound as shown in formula (I), which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. In addition, provided are a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.

Abstract: Provided is an oxygen-substituted six-membered ring pyrimidine compound with selective inhibitory effect on KRAS gene mutation and a pharmaceutically acceptable salt, a stereoisomer, a solvate, or a prodrug thereof, as represented by formula (I). The definition of each group or symbol in the formula is detailed in the specification. Moreover, a pharmaceutical composition containing the compound and an application thereof in the preparation of cancer drugs are also provided.

Abstract: An oxaazaquinazolin-7(8H)-ketone compound with a selective inhibition effect on KRAS gene mutation and pharmaceutically acceptable salts thereof, stereoisomers, solvent compounds or prodrugs (as shown in formula I or formula II, see the details of the definition to each group in the formulas in the specification), as well as the pharmaceutical composition containing the compound, and the application thereof in preparation of cancer medicine.

Abstract: A substituted dihydropyrazole compound as shown in formula I, which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, wherein the definition of each group in the formula is detailed in the description. In addition is a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.

Abstract: A substituted heterocyclic amide compound having a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and the use of same in the preparation of a drug for treating a RIPK1-related diseases or conditions.

Abstract: The present invention relates to a sulfuryl-substituted benzoheterocyclic derivative, a preparation method and medical use thereof. Particularly, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a preparation method and application thereof. The definition of each group in the formula can be found in the specification and the claims.

Abstract: The present application provides a method for preparing lanthanide fluoride two-dimensional porous nanosheets and belongs to the field of novel materials. In the present application, mixing a water-soluble lanthanide metal salt and an aqueous solution of sodium acetate in a nitrogen atmosphere to obtain a mixed solution, and adding an aqueous solution of fluorine-containing salt to the mixed solution obtained for precipitation reaction to produce lanthanide fluoride two-dimensional porous nanosheets. In the preparation process provided by the present application, no additional surfactant or template agent needs to be added, the pollution of the surfactant to the surface of the prepared material is avoided and the tedious after-treatment steps to template agent are reduced. Accordingly, the large-scale production can be realized, and the lanthanide fluoride two-dimensional porous nanosheets constructed by nanoparticles are prepared in large scale by one step.

Abstract: The present application provides a method for preparing lanthanide fluoride two-dimensional porous nanosheets and belongs to the field of novel materials. In the present application, mixing a water-soluble lanthanide metal salt and an aqueous solution of sodium acetate in a nitrogen atmosphere to obtain a mixed solution, and adding an aqueous solution of fluorine-containing salt to the mixed solution obtained for precipitation reaction to produce lanthanide fluoride two-dimensional porous nanosheets. In the preparation process provided by the present application, no additional surfactant or template agent needs to be added, the pollution of the surfactant to the surface of the prepared material is avoided and the tedious after-treatment steps to template agent are reduced. Accordingly, the large-scale production can be realized, and the lanthanide fluoride two-dimensional porous nanosheets constructed by nanoparticles are prepared in large scale by one step.

Abstract: The present invention relates to a sulfonyl-substituted benzoheterocyclic derivative, a preparation method and medical use thereof. Particularly, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a preparation method and application thereof. The definition of each group in the formula can be found in the specification and the claims.